Monthly Archives: May 2020

Merck makes major moves to enter the COVID-19 arena

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com       COVID-19 SPECIAL REPORT #20.18       Merck makes major moves to enter the COVID-19 arena       Merck, one of the largest and most innovative biopharmaceutical company, announced a triple play to enter the COVID-19 arena. Merck, a major vaccine […]

read more

AstraZeneca’s AZD1222 COVID-19 vaccine enters phase 2/3 clinical trial

      Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com         SPECIAL REPORT #20.17     AstraZeneca’s AZD1222 COVID-19 vaccine enters phase 2/3 clinical trial       In the previous report we have mentioned the positive interim phase 1 results from Moderna with its mRNA-1273 vaccine against SARS-COV-2.   […]

read more

Moderna Announces Positive Interim Phase 1 Results with mRNA-1273

  Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #20.16     Moderna Announces Positive Interim Phase 1 Results with mRNA-1273 Against COVID-19     Moderna, a Cambridge, Massachusetts (USA) based biotechnology company announced positive interim clinical data of mRNA-1273, its vaccine candidate against SARS-Cov-2) from the phase 1 study led […]

read more

News on Coronavirus Treatments

  Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #20.14     News on Coronavirus Treatments     Within the last days the US FDA has granted an emergency approval for two agents linked with the COVID-19 diagnostic and treatment.   On Sunday May 3rd, Roche received a green light for […]

read more